Telaprevir Shows Promise in Those Co-Infected with Hepatitis C and HIV
Share
Follow Us
The Editors at Hepatitis Central
March 15, 2011
Preliminary results from a Phase 2 trial demonstrated that 70 percent of people co-infected with Hepatitis C and HIV had undetectable levels of Hepatitis C after just four weeks of treatment with telaprevir.
Phase 2 Trial Shows Telaprevir Lowers Hepatitis C Viral Levels In People With HIV And Hepatitis C (CROI 2011)
By April Clayton
Published: Mar 4, 2011
Interim results from a Phase 2 trial showed that the investigational drug telaprevir lowers hepatitis C viral levels in people infected with both HIV and hepatitis C. Results also showed that telaprevir is well tolerated and safe to use, causing mild side effects such as nausea and fever.
Continue reading this entire article:
http://www.aidsbeacon.com/news/2011/03/04/phase-2-trial-shows-telaprevir-lowers-hepatitis-c-viral-levels-in-people-with-hiv-aids-and-hepatitis-c-croi-2011/
